<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="833">
  <stage>Registered</stage>
  <submitdate>11/09/2005</submitdate>
  <approvaldate>11/09/2005</approvaldate>
  <nctid>NCT00193869</nctid>
  <trial_identification>
    <studytitle>SuperDEX Trial (Comparison of Two Doses of Dexamethasone for Malignant Spinal Cord Compression Treated by Radiotherapy).</studytitle>
    <scientifictitle>A Pilot Randomised Comparison of Dexamethasone 96 mg Versus 16 mg Per Day for Malignant Spinal Cord Compression Treated by Radiotherapy</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>TROG 01.05</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Spinal Cord Compression From Neoplasm Metastasis</healthcondition>
    <conditioncode>
      <conditioncode1>Injuries and Accidents</conditioncode1>
      <conditioncode2>Other injuries and accidents</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Dexamethasone

Treatment: drugs: Dexamethasone


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Satisfactory recruitment</outcome>
      <timepoint>Failure to accrue 30 patients in 15 months will initiate early closure of this study.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Acceptable steroid toxicity rate at 28 days with reference to baseline.</outcome>
      <timepoint>28 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Ambulation rates at 1 month</outcome>
      <timepoint>1 month</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Barthel Index</outcome>
      <timepoint>Final analysis when all patients have been followed for 1 month</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Functional Independence (FIM)</outcome>
      <timepoint>Final analysis when all patients have been followed for 1 month</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Functional Improvement Score (FIS)within 2 weeks with reference to baseline</outcome>
      <timepoint>2 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Pain</outcome>
      <timepoint>Final analysis when all patients have been followed for 1 month</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Malignant spinal cord compression with at least one of pain, weakness, sensory
             disturbance or sphincter disturbance

          -  Histology not required if prior biopsy proven malignancy

          -  Any stage

          -  Age &gt;16 years

          -  ECOG 1-3 prior to cord compression event

          -  Minimum power 1 of 5 point scale Must not be paraplegic

          -  Minimum expected survival 2 months

          -  Relevant minimum lab values

          -  Patients capable of childbearing using adequate contraception

          -  Written informed consent</inclusivecriteria>
    <inclusiveminage>17</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Prior radiotherapy to within vertebralÂ±one level affected by cord compression

          -  Prior treatment for spinal cord compression at the current level

          -  Histology is lymphoma or myeloma

          -  Power less than 1 of 5

          -  More than 12 hours after initiation of dexamethasone&gt;4mg/24hr

          -  Pre-existing co-morbid conditions  peptic ulceration or cardiac failure

          -  Allergy to study medications

          -  Multilevel cord compression or meningeal carcinomatosis

          -  Pregnant or lactating</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2001</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>20</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2003</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>St George Hospital - Kogarah</hospital>
    <postcode>2217 - Kogarah</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Trans-Tasman Radiation Oncology Group (TROG)</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Cancer Council New South Wales</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study aimed to pilot the viability of a full scale randomised comparison of 2 steroid
      doses in malignant spinal cord compression, to establish safety of high dose dexamethasone in
      this setting in Australia, to test web registration and randomisation and to compare
      different functional outcome measures.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00193869</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Peter Graham, FRANZCR</name>
      <address>St George Hospital</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>